Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole

被引:47
作者
Balashov, SV
Gardiner, R
Park, S
Perlin, DS
机构
[1] Int Ctr Publ Hlth, Publ Hlth Res Inst, Newark, NJ 07103 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA
关键词
D O I
10.1128/JCM.43.1.214-222.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Aspergillus fumigatus is an important cause of life-threatening invasive fungal disease in patients with compromised immune systems. Resistance to itraconazole in A. fumigatus is closely linked to amino acid substitutions in Cyp51A that replace Gly54. In an effort to develop a new class of molecular diagnostic assay that can rapidly assess drug resistance, a multiplexed assay was established. This assay uses molecular beacons corresponding to the wild-type cyp51A gene and seven mutant alleles encoding either Arg54, Lys54, Val54, Trp54, or Glu54. Molecular beacon structure design and real-time PCR conditions were optimized to increase the assay specificity. The multiplex assay was applied to the analysis of chromosomal DNA samples from a collection of 48 A. fumigatus clinical and laboratory-derived isolates, most with reduced susceptibility to itraconazole. The cyp51A allelic identities for codon 54 were established for all of the strains tested, and mutations altering Gly54 in 23 strains were revealed. These mutations included G(54)W (n = 1), G(54)E (n = 12), G(54)K (n = 3), G(54)R (n = 3), and G(54)V (n = 4). Molecular beacon assay results were confirmed by DNA sequencing. Multiplex real-time PCR with molecular beacons is a powerful technique for allele differentiation and analysis of resistance mutations that is dynamic and suitable for rapid high-throughput assessment of drug resistance.
引用
收藏
页码:214 / 222
页数:9
相关论文
共 48 条
[31]   Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis [J].
Mennink-Kersten, MASH ;
Donnelly, JP ;
Verweij, PE .
LANCET INFECTIOUS DISEASES, 2004, 4 (06) :349-357
[32]   Antifungal drug resistance in Aspergillus [J].
Moore, CB ;
Sayers, N ;
Mosquera, J ;
Slaven, J ;
Denning, DW .
JOURNAL OF INFECTION, 2000, 41 (03) :203-220
[33]   Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole [J].
Nascimento, AM ;
Goldman, GH ;
Park, S ;
Marras, SAE ;
Delmas, G ;
Oza, U ;
Lolans, K ;
Dudley, MN ;
Mann, PA ;
Perlin, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1719-1726
[34]  
National Committee for Clinical Laboratory Standard, 1998, REF METH BROTH DIL A
[35]   Rapid identification of Candida dubliniensis using a species-specific molecular beacon [J].
Park, S ;
Wong, M ;
Marras, SAE ;
Cross, EW ;
Kiehn, TE ;
Chaturvedi, V ;
Tyagi, S ;
Perlin, DS .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (08) :2829-2836
[36]   Voriconazole: A new triazole antifungal agent [J].
Pearson, MM ;
Rogers, D ;
Cleary, JD ;
Chapman, SW .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) :420-432
[37]  
Perlin DS, 2001, REV MED MICROBIOL, V12, pS13
[38]   Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Doern, GV ;
Brandt, ME ;
Hajjeh, RA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (04) :217-222
[39]   Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods:: Report from the ARTEMIS global antifungal susceptibility program, 2001 [J].
Pfaller, MA ;
Diekema, DJ ;
Messer, SA ;
Boyken, L ;
Hollis, RJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1440-1446
[40]   Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons:: Implications for rapid susceptibility testing [J].
Piatek, AS ;
Telenti, A ;
Murray, MR ;
El-Hajj, H ;
Jacobs, WR ;
Kramer, FR ;
Alland, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :103-110